Recursion Pharmaceuticals, Inc.
RXRX
$4.64
$0.317.16%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 224.35% | -82.57% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 224.35% | -82.57% | |||
| Cost of Revenue | 36.30% | 28.21% | |||
| Gross Profit | -28.27% | -75.89% | |||
| SG&A Expenses | -29.30% | 104.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.39% | 51.42% | |||
| Operating Income | -4.07% | -86.95% | |||
| Income Before Tax | -13.27% | -86.99% | |||
| Income Tax Expenses | -2,357.14% | -95.81% | |||
| Earnings from Continuing Operations | -13.18% | -86.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.18% | -86.67% | |||
| EBIT | -4.07% | -86.95% | |||
| EBITDA | -0.65% | -87.51% | |||
| EPS Basic | 5.58% | -56.96% | |||
| Normalized Basic EPS | 5.53% | -57.33% | |||
| EPS Diluted | 6.05% | -57.38% | |||
| Normalized Diluted EPS | 5.53% | -57.33% | |||
| Average Basic Shares Outstanding | 19.86% | 18.92% | |||
| Average Diluted Shares Outstanding | 19.86% | 18.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||